SEARCH

SEARCH BY CITATION

References

  • 1
    Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985; 31: 148.
  • 2
    Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986; 91: 13431346.
  • 3
    Such J, Guarner C, Enríquez J, Rodríguez JL, Serés I, Vilardell F. Low C3 in ascitic fluid predisposes to spontaneous bacterial peritonitis. J Hepatol 1988; 6: 8084.
  • 4
    Soriano G, Guarner C, Teixidó M, Such J, Barrios J, Enríquez J, Vilardell F. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477481.
  • 5
    Andreu M, Solà R, Sitges-Serra A, Alia C, Gallen M, Vila MC, Coll S, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104: 11331138.
  • 6
    Llach J, Rimola A, Navasa M, Gines P, Salmeron JM, Gines A, Arroyo V, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology 1992; 16: 724727.
  • 7
    Guarner C, Runyon BA. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, and management. Gastroenterologist 1995; 3: 311328.
  • 8
    Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: an update. Mayo Clin Proc 1995; 70: 365370.
  • 9
    Felisart J, Rimola A, Arroyo V, Pérez-Ayuso RM, Quintero E, Ginès P, Rodés J. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985; 5: 457462.
  • 10
    Toledo C, Salmerón JM, Rimola A, Navasa M, Arroyo V, Llach J, Ginès A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17: 251257.
  • 11
    Llovet JM, Planas R, Morillas R, Quer JC, Cabré E, Boix J, Humbert P, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993; 88: 388392.
  • 12
    Titó LI, Rimola A, Ginès P, Llach J, Arroyo V, Rodés J. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 2731.
  • 13
    Rimola A, Bory F, Planas R, Xaubet A, Bruguera M, Rodés J. Infecciones bacterianas en la cirrosis hepática. Gastroenterol Hepatol 1981; 4: 453458.
  • 14
    Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18: 353358.
  • 15
    Rimola A, Bory F, Terés J, Pérez-Ayuso RM, Arroyo V, Rodés J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5: 463467.
  • 16
    Ginés P, Rimola A, Planas R, Vargas V, Marco F, Almela M, Forné M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-con trolled trial. Hepatology 1990; 12: 716724.
  • 17
    Such J, Guarner C, Soriano G, Teixidó M, Barrios J, Tena F, Méndez C, et al. Selective intestinal decontamination increases serum and ascitic fluid C3 levels in cirrhosis. Hepatology 1990; 12: 11751178.
  • 18
    van der Waaij D, Manson WL, Arends JP, de Vries Hospers HG. Clinical use of selective decontamination: the concept. Intensive Care Med 1990; 16 (suppl 3): s212216.
  • 19
    Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 1988; 14: 96121.
  • 20
    Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D, Sainz S, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal bleeding. Gastroenterology 1992; 103: 12671272.
  • 21
    Singh N, Gayowski T, Yu VL, Wagener M. Trimethoprim-sulfamethoxa-zole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995; 122: 595598.
  • 22
    Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, Fratte S, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995; 22: 11711174.
  • 23
    Zinner SH, Mayer KH. Sulfonamides and trimethoprim. In: MandellGL, BennettJE, DolinR, eds. Principles and practice of infectious diseases. Vol 1, Ed 4. New York: Churchill Livingstone, 1995: 354364.
  • 24
    Runyon BA, Canawati HN, Akriviadis EA. Optimization of ascitic fluid culture technique. Gastroenterology 1988; 95: 13511355.
  • 25
    Grange JD, Amiot X, Grange V, Gutmann L, Biour M, Bodin F, Poupon R. Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients. Hepatology 1990; 11: 360364.
  • 26
    Runyon BA, Borzio M, Young S, Squier S, Guarner C, Runyon MA. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation and survival in an animal model of cirrhosis. Hepatology 1995; 21: 17191724.
  • 27
    Tomás A, Soriano G, Guarner C, Portorreal R, Novella MT, Vilardell F. Hospital-acquired bacterial infections in patients with cirrhosis undergoing selective intestinal decontamination [Letter]. J Hepatol 1993; 18: 262263.
  • 28
    Muder RR, Brennen C, Goetz AM, Wagener MM, Rihs JD. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs Medical Center. Antimicrob Agents Chemother 1991; 35: 256258.
  • 29
    Peña C, Albareda JM, Parrarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escke-richia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39: 520524.
  • 30
    Murray BE. Can antibiotic resistance be controlled? N Engl J Med 1994; 330: 12291230.
  • 31
    Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 12401241.
  • 32
    Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994; 38: 340344.
  • 33
    Castellote J, Xiol J, Rota R, Fernández G. Spontaneous bacterial peritonitis and empyema by Escherichia coli resistant to norfloxacin in a patient on selective intestinal decontamination with norfloxacin [Letter]. J Hepatol 1994; 20: 436.
  • 34
    Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122128.